CAS: 7234-25-5; Ethyl 4-Methyl-2-(Methylthio)-5-Pyrimidinecarboxylate

相似化合物

17759-40-9 84755-30-6 98276-75-6

上下游产品

CAS号14527-26-5 S-甲基异硫脲硫酸盐 | CAS号3788-94-1 2-乙氧亚甲基乙酰乙酸乙酯 | CAS号2986-19-8 2-甲基-2-疏基硫酸脲 | CAS号141-97-9 乙酰乙酸乙酯 | CAS号630-19-3 三甲基乙醛 | CAS号66975-53-9 ethoxymethylene... | CAS号78-84-2 异丁醛 | CAS号134653-70-6 2-Dimethylamino... | CAS号108123-81-5 Ethyl 2-(benzyl... | CAS号81633-29-6 2-氨基-4-甲基嘧啶-5-羧酸乙酯 | CAS号98276-75-6 4-甲基-2-(甲硫基)嘧啶-5-羧酸 | CAS号14001-63-9 4-甲基-2-甲硫基嘧啶 | CAS号902576-09-4 2-(甲硫基)吡啶并[4,3-... | CAS号509101-17-1 ETHYL 4-METHYL-...

1,4-二氢-4-异丙基-6-甲基-2-(甲硫基)嘧啶-5-羧酸乙酯置于碘苯二乙酸体系中,用 二氯甲烷 作为反应溶剂,化学反应 1.0H,以69%的收率获得产物4-甲基-2-甲硫基嘧啶-5-甲酸乙酯
参考文献:使用(二乙酰氧基碘)苯进行4-取代-1,4-二氢嘧啶的轻度和高效氧化芳构化
标题:使用(二乙酰氧基碘)苯进行4-取代-1,4-二氢嘧啶的轻度和高效氧化芳构化
摘要:4-烷基或芳基-1,4-二氢嘧啶很容易在温和的反应条件下被(二乙酰氧基碘)苯氧化为相应的嘧啶衍生物,收率很好.j.杂环化学.(2010).
DOI:10.1002/jhet.389

专利信息

专利号:US-7196090-B2
优先权日:2002-07-25
标题 :Kinase inhibitors
发明人：CONNOLLY CLEO J CHIVIKAS; DEUR CHRISTOPHER JAMES; HAMBY JAMES MARINO; HOYER DENTON WADE; LIMBERAKIS CHRIS; REED JESSICA ELIZABETH; SCHROEDER MEL CONRAD; TAYLOR CLARKE
权利人:WARNER LAMBERT CO
摘要:This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: n nthat inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis, as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.

专利号:US-11014926-B2
优先权日:2015-10-29
标 题 :Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2
发明人：SPRENGELER PAUL A; REICH SIEGFRIED H; ERNST JUSTIN T; WEBBER STEPHEN E
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n nFor Formula I compounds A 1 , A 2 . A 3 , A 4 , A 5 , A 6 , A 7 , W 1 , R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 7a , R 7b , R 8 , R 8a , R 8b , R 9 , R 9a , R 9b and R 10 and subscripts “mâ€? and “nâ€? are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.